AHAhmad Hassan

Ahmad Hassan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmad Hassan has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Indobufen Versus Aspirin in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

    by Ahmad Hassan, Muhammad Rayyan Yousafi, Muhammad Essa, Affaf Mahmood, Ahmed Asif, Muhammad Sarmad, Usama Ahmad, Amna Iman, Semil Saleem, Kanza Raees, et al.

    Background: Acute ischemic stroke (AIS) is a major cause of death and disability worldwide. Early antiplatelet therapy reduces recurrence and improves outcomes. Although aspirin is standard treatment, its use is limited by bleeding risk. Indobufen, a reversible cyclooxygenase inhibitor with shorter platelet inhibition, may offer a safer alternative. Objective: To compare the efficacy and safety of indobufen versus aspirin in patients with AIS. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. PubMed, Embase, Cochrane Library, and ScienceDirect were searched through February 2026 for randomized controlled trials comparing indobufen with aspirin in adults with AIS. Primary outcomes were functional outcomes (modified Rankin Scale), neurological improvement (NIHSS) at 90 days, recurrent ischemic stroke at 90 days, and composite vascular events. Secondary outcomes included bleeding and other adverse events. Pooled estimates were calculated using fixed- or random-effects models based on heterogeneity. The risk of bias was assessed using Cochrane RoB 2.0. Results: Four randomized controlled trials (278 records screened) were included. Indobufen showed no significant difference versus aspirin in NIHSS improvement at 90 days (MD: 0.01, 95% CI: −0.07 to 0.09) or recurrent ischemic stroke (OR: 0.54, 95% CI: 0.05-5.61). However, indobufen significantly improved modified Rankin Scale outcomes (MD: −1.11, 95% CI: −1.32 to −0.90) and reduced moderate-to-severe bleeding at 3 months (OR: 0.57, 95% CI: 0.35-0.92). Conclusions: Indobufen provides efficacy comparable to aspirin, with better functional outcomes and lower short-term bleeding risk, supporting its potential as an alternative antiplatelet therapy in AIS. Larger, international, multicenter trials are warranted. Larger, high-quality, multicenter international trials are warranted to confirm these findings.

  • Open Access

    Perioperative dexmedetomidine for the prevention of postoperative delirium in elderly patients undergoing orthopedic surgery: a systematic review and meta-analysis of randomized controlled trials

    by Syed Faqeer Hussain Bokhari, Affaf Mahmood, Saira Shamim, Khansa Mehmood, Rabia Amjad, Abdul Saboor Khan, Aiman Jeet Kaur, Ibrahim Salau, Fnu Maryam, Ahmad Hassan, et al.

    Background: Postoperative delirium (POD) is a frequent and morbid complication in elderly patients undergoing orthopedic surgery. Although dexmedetomidine has been studied for delirium prevention in mixed surgical populations, evidence specific to orthopedic procedures and perioperative administration strategies remains fragmented. Objective: To evaluate the efficacy and cardiovascular safety of perioperative dexmedetomidine for POD prevention in elderly patients undergoing orthopedic surgery and to examine its impact on recovery outcomes. Methods: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials (RCTs) comparing perioperative dexmedetomidine with placebo or standard care in adults undergoing orthopedic surgery was conducted. The primary outcome was POD incidence. Secondary outcomes included time-specific delirium, perioperative cardiovascular adverse events, length of hospital stay, in-hospital complications, and mortality. Results: Seven RCTs, including 2060 patients, were analyzed. Dexmedetomidine significantly reduced overall POD incidence [odds ratio (OR) = 0.42; 95% CI 0.32–0.54; I 2 = 0%; P < 0.00001]. Time-specific reductions were observed at 24 h (OR = 0.36; 95% CI 0.22–0.57; P < 0.0001) and 72 h (OR = 0.46; 95% CI 0.24–0.87; P = 0.02), but not at 48 h (OR = 0.38; 95% CI 0.12–1.15; P = 0.09). Intraoperative cardiovascular adverse events were increased overall (OR = 1.65; 95% CI 1.10–2.47; P = 0.02), while individual events were not significantly different. Postoperatively, hypertension was reduced (OR = 0.52; 95% CI 0.30–0.91; P = 0.02). Hospital stay was significantly shorter (mean difference = −1.31 days; 95% CI −1.93 to −0.69; P < 0.0001), with no significant differences in in-hospital complications (OR = 0.74; P = 0.06) or mortality (OR = 0.89; P = 0.83). Conclusion: Perioperative dexmedetomidine reduces POD and improves recovery in elderly orthopedic patients, with manageable cardiovascular effects under monitoring. Further large-scale trials are needed to determine optimal dosing, timing, and long-term neurocognitive outcomes.

  • Open Access

    Association of oral vancomycin prophylaxis with Clostridium difficile infection in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis

    by Maaz Amir, Khkula Kamal, Muhammad Asad Jahangir, Muneeb Faiz, Zonaira Mushahid, Mohammad Mujtaba Khokhar, Ayesha Wasim, Muhammad Sarmad, Asad Ullah Mehboob, Muhammad Moneeb Anwar, et al.

    Background: Clostridium difficile infection (CDI) occurs in up to 30% of hematopoietic stem cell transplant (HSCT) recipients and remains a significant cause of infectious diarrhea. This meta-analysis evaluated the association of oral vancomycin prophylaxis (OVP) with CDI prevention after HSCT. Methods: We conducted a literature search of PubMed, Cochrane, and Google Scholar for articles from inception to July 2025 that compared the safety and efficacy of OVP for CDI in post-HSCT patients. Statistical analysis of the extracted data was conducted using Review Manager 5.4. The odds ratio for dichotomous variables and the mean difference for continuous variables were analyzed along with the corresponding 95% confidence intervals. A random-effects model was applied when heterogeneity was high ( I 2 ≥ 50%), and a fixed-effect model was applied when heterogeneity was low ( I 2 ≤ 50%). Results: This meta-analysis included 5 studies comprising 957 patients, with 490 (51.2%) receiving OVP and 467 (48.8%) not receiving OVP (no OVP). OVP was significantly associated with a reduced incidence of CDI during hospitalization ( P < .00001). Although a lower overall incidence of CDI (hospitalization plus 180-day follow-up) was observed in the OVP group, the result was not statistically significant ( P = .06). A leave-one-out analysis was performed to establish a significant association ( P = .04). In the OVP group, higher rates of grade 2 to 4 acute graft-versus-host disease ( P = .13) and lower rates of bloodstream infections ( P = .74), 1-year event-free survival ( P = .44), and longer hospital stays ( P = .36) were observed, although none reached statistical significance. Conclusion: We conclude that oral vancomycin might be associated with a lower incidence of CDI during hospitalization in post-HSCT recipients and can be considered for CDI prophylaxis. No statistically significant adverse outcomes were observed in the OVP group compared with placebo. However, given the observational nature of these studies, these findings should be considered preliminary. Large-scale randomized controlled trials are needed to confirm the true efficacy and safety profile of OVP in post-HSCT recipients.

  • Minimally Invasive vs. Open Pancreaticoduodenectomy for Distal Cholangiocarcinoma: A Systematic Review and Meta-analysis

    by Danyal Bakht, Azmir Ali Khan, Hafsa Hashmi, Maaz Amir, Ubaid Ur Rehman, Affaf Mahmood, Mehrab Naeem, Muhammad Ahmad Raza, Fatima Naeem, Arbab Sarfraz, et al.

    Background Distal cholangiocarcinoma (dCCA) is a rare but aggressive biliary malignancy arising from the distal bile duct with significant clinical burden. Pancreaticoduodenectomy (minimally invasive or open) remains the only potentially curative treatment for dCCA. However, the comparative safety and oncologic adequacy of minimally invasive versus open pancreaticoduodenectomy remains unclear, creating an evidence gap that this systematic review addresses. Objective This systematic review and meta-analysis aimed to compare perioperative outcomes and oncologic effectiveness of MIPD versus OPD in patients undergoing surgery for distal cholangiocarcinoma. Methods A systematic literature search of PubMed, Embase, Cochrane Library, and Science Direct was conducted through April 2025 in accordance with PRISMA guidelines. Eligible studies included cohort studies, randomized controlled trials, and case-control studies comparing MIPD (laparoscopic or robotic) with OPD in dCCA. Data regarding operative parameters, oncologic outcomes, perioperative morbidity, and mortality were extracted. Meta-analysis was performed using Review Manager 5.4, applying fixed- or random-effects models based on heterogeneity. Results Seven retrospective cohort studies comprising 1,803 patients (775 MIPD vs. 1,028 OPD) were included. MIPD was associated with significantly lower blood loss (WMD − 100.86 mL, 95% CI − 107.27 to − 94.46; I² = 90%; p < 0.001) and shorter hospital stay (WMD − 2.46 days, 95% CI − 4.08 to − 0.84; I² = 89%; p = 0.003), but longer operative time (WMD 52.60 min, 95% CI 16.82 to 88.39; I² = 99%; p = 0.004). There was no significant difference in major complications (Clavien-Dindo ≥ III) (OR 0.97, 95% CI 0.74–1.28; p = 0.85) or postoperative mortality (OR 0.46, 95% CI 0.16–1.33; I² = 56%; p = 0.15) between groups. Importantly, long-term oncologic outcomes were also comparable between groups, with no significant differences observed in overall survival (HR 0.90, 95% CI 0.77–1.05; p = 0.19) or disease-free survival (HR 0.98, 95% CI 0.83–1.16; p = 0.83). No survival disadvantage was demonstrated for MIPD compared with OPD. Conclusion MIPD appears to be a safe and feasible alternative to OPD for selected patients with distal cholangiocarcinoma, offering perioperative benefits without compromising oncologic outcomes. Importantly, available evidence also demonstrates no compromise in long-term oncologic outcomes, with comparable overall and disease-free survival between MIPD and OPD. However, given the rarity of dCCA, stand-alone randomized controlled trials are unlikely to be feasible. Future evidence should therefore focus on stratifying dCCA patients within ongoing or future multicenter trials of minimally invasive pancreaticoduodenectomy for periampullary malignancies, as well as prospective international registry-based studies with mandatory reporting of histological subtypes to generate high-quality, generalizable evidence.